Zinbryta receives TGA approval in Australia for use in relapsing MS

The Australian Therapeutic Goods Administration (TGA) has approved the registration of disease modifying multiple sclerosis (MS) medication, Zinbryta (daclizumab) on the Australian Register of Therapeutic Goods. To read more, click on the link below:

zinbryta-receives-tga-approval-in-australia-for-use-in-relapsing-ms

Article courtesy of MS Research Australia www.msra.org.au